Q2 2026 saw strong revenue and net income growth, with both GAAP and non-GAAP margins improving year-over-year. Updated FY 2026 guidance projects 8% revenue growth and 11–14% non-GAAP EPS growth, supported by robust domestic and international sales.Original document: Merit Medical Systems, Inc. [MM…
Q2 2026 saw strong revenue and net income growth, with both GAAP and non-GAAP margins improving year-over-year. Updated FY 2026 guidance projects 8% revenue growth and 11–14% non-GAAP EPS growth, supported by robust domestic and international sales.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
